abstract |
The present invention provides a treatment with an IL-6 antagonist having binding specificity for IL-6, such as an Ab1 antibody or antibody fragment, to prevent or treat a disease, or to improve the viability or quality of life of a sick patient. It is about how. In preferred embodiments, these patients have elevated serum C-reactive protein levels, reduced serum albumin levels, elevated D-dimer or other coagulation cascade related protein (s), cachexia, fever prior to treatment. And patients exhibiting weakness and / or fatigue (or at risk of developing them). The therapy of the present invention may also include administration of other active agents, such as chemotherapeutic agents, anti-coagulants, statins, and the like. |